• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕唑帕尼治疗肾癌的安全性和耐受性。

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.

机构信息

Department of Medical Oncology, San Camillo-Forlanini Hospital, Circonvallazione Gianicolense 87, 00152, Rome, Italy.

出版信息

Expert Opin Drug Saf. 2012 Sep;11(5):851-9. doi: 10.1517/14740338.2012.712108. Epub 2012 Aug 4.

DOI:10.1517/14740338.2012.712108
PMID:22861374
Abstract

INTRODUCTION

Renal cell carcinoma (RCC) is still a challenging disease. Over the last 6 years, the use of novel targeted therapies interfering with vascularization and inhibition of other downstream pathways has revolutionized the therapy of this disease, leading to an improvement of patient outcomes. In particular, dysregulation of the vascular endothelial growth factor (VEGF) pathway and VEGF protein overexpression have proved important, as they result in increased tumor angiogenesis and RCC growth and development.

AREAS COVERED

This review briefly discusses the mechanisms of action and clinical applications of pazopanib . It mainly outlines the safety and tolerability of pazopanib for locally advanced/metastatic RCC. Phase III pazopanib safety data are also indirectly compared with other standard, antiangiogenic receptor tyrosine kinase inhibitors currently used in the management of RCC.

EXPERT OPINION

Pazopanib is a new drug available in the oncology portfolio to treat patients with predominantly clear-cell RCC. The toxicity profile of pazopanib is comparable, but in some ways distinct, from other antiangiogenic drugs used in the treatment of RCC. Long-term data about late side effects of this treatment are awaited.

摘要

简介

肾细胞癌(RCC)仍然是一种具有挑战性的疾病。在过去的 6 年中,新型靶向治疗药物的使用干扰了血管生成和抑制其他下游途径,彻底改变了这种疾病的治疗方法,改善了患者的预后。特别是,血管内皮生长因子(VEGF)途径的失调和 VEGF 蛋白的过度表达被证明是重要的,因为它们导致肿瘤血管生成增加以及 RCC 的生长和发展。

涵盖领域

本文简要讨论了帕唑帕尼的作用机制和临床应用。它主要概述了帕唑帕尼治疗局部晚期/转移性 RCC 的安全性和耐受性。还间接比较了帕唑帕尼的 III 期安全性数据与目前用于 RCC 治疗的其他标准抗血管生成受体酪氨酸激酶抑制剂。

专家意见

帕唑帕尼是肿瘤学组合中的一种新药,用于治疗主要为透明细胞 RCC 的患者。帕唑帕尼的毒性谱与其他用于治疗 RCC 的抗血管生成药物相似,但在某些方面有所不同。正在等待关于这种治疗方法晚期副作用的长期数据。

相似文献

1
Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.帕唑帕尼治疗肾癌的安全性和耐受性。
Expert Opin Drug Saf. 2012 Sep;11(5):851-9. doi: 10.1517/14740338.2012.712108. Epub 2012 Aug 4.
2
Pazopanib for the treatment of renal cancer.帕唑帕尼治疗肾癌。
Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7.
3
Pazopanib for the treatment of metastatic renal cell carcinoma.帕唑帕尼治疗转移性肾细胞癌。
Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16.
4
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.帕唑帕尼,一种用于治疗肾细胞癌的强效口服小分子多靶点酪氨酸激酶抑制剂。
Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253.
5
Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.帕唑帕尼:软组织肉瘤治疗中一种有前途的新药。
Future Oncol. 2011 Dec;7(12):1373-83. doi: 10.2217/fon.11.116.
6
Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.帕唑帕尼:一种用于局部晚期或转移性肾细胞癌的口服多靶点酪氨酸激酶抑制剂。
Can J Urol. 2011 Dec;18(6):5991-7.
7
Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.帕唑帕尼治疗的护理考量:聚焦转移性肾细胞癌
Clin J Oncol Nurs. 2011 Oct;15(5):513-7. doi: 10.1188/11.CJON.513-517.
8
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.帕唑帕尼:治疗晚期或转移性肾细胞癌的最新酪氨酸激酶抑制剂。
Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000.
9
Pazopanib outscores sunitinib on tolerability.帕唑帕尼在耐受性方面优于舒尼替尼。
Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.
10
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.帕唑帕尼治疗晚期和/或转移性肾细胞癌患者的随机、双盲 III 期研究:最终总生存结果和安全性更新。
Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12.

引用本文的文献

1
Recent Advances in Synthetic Strategies and Biological Properties of Indazole Scaffolds: A Review.吲唑骨架的合成策略与生物学特性的最新进展:综述
Top Curr Chem (Cham). 2025 Jul 1;383(3):26. doi: 10.1007/s41061-025-00509-9.
2
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol.酪氨酸激酶抑制剂(TKI)的治疗药物监测(TDM)以优化转移性肾细胞癌患者的治疗效果。TKI-TDM试验。研究方案。
Acta Oncol. 2025 Jun 2;64:729-733. doi: 10.2340/1651-226X.2025.43693.
3
Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature.
骨骼转移瘤的现代治疗:近期文献中的多学科性与寡转移概念
Curr Oncol. 2025 Apr 11;32(4):226. doi: 10.3390/curroncol32040226.
4
Pathophysiology in Brain Arteriovenous Malformations: Focus on Endothelial Dysfunctions and Endothelial-to-Mesenchymal Transition.脑动静脉畸形的病理生理学:聚焦于内皮功能障碍和内皮-间充质转化
Biomedicines. 2024 Aug 7;12(8):1795. doi: 10.3390/biomedicines12081795.
5
Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review.肾癌的分子洞察及最新治疗方法:一篇更新综述
Med Oncol. 2023 Nov 13;40(12):355. doi: 10.1007/s12032-023-02225-0.
6
Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy.病例报告:肾切除术后16年发生肾细胞癌胰腺转移。
Front Oncol. 2023 Feb 9;13:1091635. doi: 10.3389/fonc.2023.1091635. eCollection 2023.
7
Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review.序贯抗 FGFR 治疗转移性胆囊癌的持续缓解:病例报告及文献复习。
J Cancer Res Clin Oncol. 2023 Jul;149(8):4915-4923. doi: 10.1007/s00432-022-04428-w. Epub 2022 Oct 28.
8
Pazopanib Is a Potential Treatment for Coronavirus-Induced Lung Injuries.帕唑帕尼可能是治疗冠状病毒引起的肺部损伤的一种方法。
J Immunol. 2022 Aug 15;209(4):723-730. doi: 10.4049/jimmunol.2100968. Epub 2022 Aug 1.
9
Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future.成人高级别胶质瘤中的小分子抑制剂:从过去到未来
Front Oncol. 2022 Jun 17;12:911876. doi: 10.3389/fonc.2022.911876. eCollection 2022.
10
Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3.帕唑帕尼通过抑制 MAP3K2 和 MAP3K3 改善急性肺损伤。
Sci Transl Med. 2021 Apr 28;13(591). doi: 10.1126/scitranslmed.abc2499.